Literature DB >> 10987624

Low concentrations of 17beta-estradiol protect single cardiac cells against metabolic stress-induced Ca2+ loading.

S Jovanović1, A Jovanović, W K Shen, A Terzic.   

Abstract

OBJECTIVES: The main objective of the present study was to determine whether low physiological levels of estrogen directly protect cardiac cells against metabolic stress.
BACKGROUND: The beneficial effect of estrogens on the cardiovascular system has been traditionally ascribed to decrease in peripheral vascular resistance and to an antiatherogenic action. Whether physiological concentrations of 17beta-estradiol (E2) are also able to protect cardiomyocytes against metabolic insult directly is unknown.
METHODS: Isolated ventricular cardiomyocytes were loaded with the Ca2+-sensitive fluorescent dye Fluo-3 and imaged by a digital epifluorescence imaging system. In cardiac cells preincubated with hormones and/or drugs for 8 h, metabolic stress was induced by addition and removal of 2,4-dinitrophenol (DNP).
RESULTS: In cardiomyocytes, a 3-min-long exposure to chemical hypoxia, followed by reoxygenation, produced intracellular Ca2+ loading independently of gender (female: 729 +/- 88 nmol/liter; male: 778 +/- 97 nmol/liter). Pretreatment with E2 (10 nmol/liter) significantly reduced the magnitude of hypoxia/reoxygenation-induced Ca2+ loading in female (E2-treated: 298 +/- 39 nmol/liter; untreated: 729 +/- 88 nmol/liter), but not in male (E2-treated: 1029 +/- 177 nmol/liter; untreated: 778 +/- 97 nmol/liter) cardiac cells. The protective action of E2 was not mimicked by the inactive estrogen stereoisomer, 10 nmol/liter 17alpha estradiol (17alpha estradiol-treated: 886 +/- 122 nmol/liter; untreated: 729 +/- 88 nmol/liter), and was abolished by tamoxifen (1 micromol/liter), which acts as an antagonist of E2 on estrogen receptors (E2 plus tamoxifen-treated: 702 +/- 98 nmol/liter; untreated: 729 +/- 88 nmol/liter).
CONCLUSIONS: In a gender-dependent manner, E2 directly protects cardiac cells against hypoxia-reoxygenation injury through an estrogen receptor-mediated mechanism. Such property of E2 may contribute to cardioprotection in the female gender.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10987624     DOI: 10.1016/s0735-1097(00)00798-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

Review 1.  Exercise-induced muscle damage and the potential protective role of estrogen.

Authors:  Becky Kendall; Roger Eston
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

2.  Specific adaptations of estrogen receptor alpha and beta transcripts in liver and heart after endurance training in rats.

Authors:  Amélie Paquette; Dongaho Wang; Marie-Soleil Gauthier; Denis Prud'homme; Marek Jankowski; Jolanta Gutkowska; Jean-Marc Lavoie
Journal:  Mol Cell Biochem       Date:  2007-08-01       Impact factor: 3.396

3.  Oestrogen confers cardioprotection by suppressing Ca2+/calmodulin-dependent protein kinase II.

Authors:  Y Ma; W T Cheng; S Wu; T M Wong
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

Review 4.  Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis.

Authors:  Darae Ko; Faisal Rahman; Renate B Schnabel; Xiaoyan Yin; Emelia J Benjamin; Ingrid E Christophersen
Journal:  Nat Rev Cardiol       Date:  2016-04-07       Impact factor: 32.419

5.  Gender differences in contrast-enhanced magnetic resonance imaging after acute myocardial infarction.

Authors:  Birgit Langhans; Tareq Ibrahim; Jörg Hausleiter; Carolin Sonne; Stefan Martinoff; Albert Schömig; Martin Hadamitzky
Journal:  Int J Cardiovasc Imaging       Date:  2012-10-09       Impact factor: 2.357

6.  Protective role of normothermic, hyperthermic and estrogen preconditioning and pretreatment on tumour necrosis factor-alpha-induced damage.

Authors:  Jasbir S Juggi; Lamia J Hoteit; Fawzi A Babiker; Shaji Joseph; Abu Salim Mustafa
Journal:  Exp Clin Cardiol       Date:  2011

Review 7.  Gender Differences in Cardiac Hypertrophy.

Authors:  Jian Wu; Fangjie Dai; Chang Li; Yunzeng Zou
Journal:  J Cardiovasc Transl Res       Date:  2019-08-15       Impact factor: 4.132

8.  Physiologic basis and pathophysiologic implications of the diastolic properties of the cardiac muscle.

Authors:  João Ferreira-Martins; Adelino F Leite-Moreira
Journal:  J Biomed Biotechnol       Date:  2010-06-02

Review 9.  [Heart failure--are there gender aspects?].

Authors:  V Regitz-Zagrosek; E Lehmkuhl; H B Lehmkuhl
Journal:  Internist (Berl)       Date:  2008-04       Impact factor: 0.743

10.  Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current.

Authors:  Reginald Liew; Mark A Stagg; Kenneth T MacLeod; Peter Collins
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.